Pediatric SU2C Catalyst® Research Grant with support from BMS: Clinical Translation of Novel Immune-Based Combination Therapies for Pediatric Hypermutant Cancers - Stand Up To Cancer

Blog

Posted October 10, 2019

Pediatric SU2C Catalyst® Research Grant with support from BMS: Clinical Translation of Novel Immune-Based Combination Therapies for Pediatric Hypermutant Cancers

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.